Gene · 7517
Papers2,149
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,149
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks. | Molecules | 2022 | 35268641 | PubTator, text mining | PubMed |
| Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted. | Cancers (Basel) | 2022 | 35267440 | PubTator, text mining | PubMed |
| Establishment and validation of a prognostic model based on HRR-related lncRNAs in colon adenocarcinoma. | World J Surg Oncol | 2022 | 35264195 | PubTator, text mining | PubMed |
| Inhibitors of PARP: Number crunching and structure gazing. | Proc Natl Acad Sci U S A | 2022 | 35259019 | PubTator, text mining | PubMed |
| Meiotic Genes and DNA Double Strand Break Repair in Cancer. | Front Genet | 2022 | 35251135 | PubTator, text mining | PubMed |
| PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers. | Biomedicines | 2022 | 35203508 | PubTator, text mining | PubMed |
| Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes. | Biomedicines | 2022 | 35203410 | PubTator, text mining | PubMed |
| The association of oxidative stress and DNA damage with XRCC1 and XRCC3 polymorphisms in radiology technicians. | Toxicol Ind Health | 2022 | 35191782 | PubTator, text mining | PubMed |
| Immediate-Early, Early, and Late Responses to DNA Double Stranded Breaks. | Front Genet | 2022 | 35173769 | PubTator, text mining | PubMed |
| Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. | JAMA Netw Open | 2022 | 35171259 | PubTator, text mining | PubMed |
| Theranostic Interpolation of Genomic Instability in Breast Cancer. | Int J Mol Sci | 2022 | 35163783 | PubTator, text mining | PubMed |
| Homologous Recombination-Enhancing Factors Identified by Comparative Transcriptomic Analyses of Pluripotent Stem Cell of Human and Common Marmoset. | Cells | 2022 | 35159172 | PubTator, text mining | PubMed |
| Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? | Cancers (Basel) | 2022 | 35159068 | PubTator, text mining | PubMed |
| Metnase and EEPD1: DNA Repair Functions and Potential Targets in Cancer Therapy. | Front Oncol | 2022 | 35155245 | PubTator, text mining | PubMed |
Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation. | J Nucl Med | 2022 | 35115370 | PubTator, text mining | PubMed |
| DNA Repair Capacity for Personalizing Risk and Treatment Response - Assay Development and Optimization in Human Peripheral Blood Mononuclear Cells (PBMCs). | DNA Repair (Amst) | 2022 | 35085879 | PubTator, text mining | PubMed |
| Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. | J Hematol Oncol | 2022 | 35065680 | PubTator, text mining | PubMed |
| Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women. | PLoS One | 2022 | 35061678 | PubTator, text mining | PubMed |
| Identification of a glioma functional network from gene fitness data using machine learning. | J Cell Mol Med | 2022 | 35044082 | PubTator, text mining | PubMed |
Integration of gene co-expression analysis and multi-class SVM specifies the functional players involved in determining the fate of HTLV-1 infection toward the development of cancer (ATLL) or neurological disorder (HAM/TSP). | PLoS One | 2022 | 35041720 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7517/papers?page=15